Matches in SemOpenAlex for { <https://semopenalex.org/work/W2230481302> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2230481302 endingPage "4640" @default.
- W2230481302 startingPage "4640" @default.
- W2230481302 abstract "4640 Background: The addition of chemotherapy (CTX) to primary treatment is being evaluated in clinical trials to improve outcomes in high-risk prostate cancer. Factors that predict relapse after combined treatment with CTX and radical prostatectomy (RP) are not known. Understanding which clinical and pathologic factors affect outcome can facilitate the design of studies of combined modality treatment of high-risk prostate cancer. Methods: Using the Kaplan-Meier method and log-rank test for univariate analyses and Cox’s proportional hazards regression for the multivariate analysis, we examined the relationship between progression-free survival (PFS, defined as time to serum PSA ≥ 0.4 ng/mL) and a series of variables in men with high risk prostate cancer (cT2b or T3a or PSA ≥ 15 ng/mL or Gleason score (GS) ≥ 4+3) who received 4 cycles of docetaxel (35 mg/m2) and mitoxantrone (2–5 mg/m2) weekly for 3 of every 4 weeks prior to RP. Pre-CTX variables were PSA, PSA density (PSAD), age, biopsy GS, and cT stage. Post-treatment variables were: CTX doses delivered, %PSA change, surgical GS, pT stage, pN stage, margin status, Ki-67 index (% Ki-67 staining cells/total cancer cells from a tissue microarray), and presence of intraductal carcinoma (IDC). Results: 48 patients received at least 1 cycle of CTX and were evaluable for efficacy endpoints. Median follow-up is 18.6 months. Estimated PFS at 2 years is 70±14%. In univariate analyses PSA ≥ 15 ng/dL (p=0.02), presence of IDC (p=0.003), and lymph node metastases (+LN) (p<0.001) were associated with shorter PFS. In a multivariate analysis of pre-treatment factors, PSAD (HR 1.25 per 0.1 ng/ml/cc, 95%CI 1.03–1.5, p=0.03) was the only factor significantly associated with shorter PFS. When both pre- and post-treatment factors were included, PSAD (HR 1.3 per 0.1 ng/ml/cc, 95%CI 1.05–1.6, p=0.02) and +LN (HR 27, 95% CI 6–125, p<0.001) were independent predictors of shorter PFS. There was a trend for biopsy GS 8–10 (HR 3.9, 95%CI 0.9–16.9, p=0.068). Conclusions: Our early results show that in high risk prostate cancer treated with neoadjuvant chemotherapy followed by radical prostatectomy, PSAD and persistent nodal disease are significantly associated with early relapse. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis, OSI" @default.
- W2230481302 created "2016-06-24" @default.
- W2230481302 creator A5001591556 @default.
- W2230481302 creator A5026692219 @default.
- W2230481302 creator A5034997866 @default.
- W2230481302 creator A5042631007 @default.
- W2230481302 creator A5042806568 @default.
- W2230481302 creator A5048477205 @default.
- W2230481302 creator A5052280145 @default.
- W2230481302 creator A5077102924 @default.
- W2230481302 creator A5078273320 @default.
- W2230481302 creator A5078873882 @default.
- W2230481302 date "2005-06-01" @default.
- W2230481302 modified "2023-09-25" @default.
- W2230481302 title "Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel" @default.
- W2230481302 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4640" @default.
- W2230481302 hasPublicationYear "2005" @default.
- W2230481302 type Work @default.
- W2230481302 sameAs 2230481302 @default.
- W2230481302 citedByCount "0" @default.
- W2230481302 crossrefType "journal-article" @default.
- W2230481302 hasAuthorship W2230481302A5001591556 @default.
- W2230481302 hasAuthorship W2230481302A5026692219 @default.
- W2230481302 hasAuthorship W2230481302A5034997866 @default.
- W2230481302 hasAuthorship W2230481302A5042631007 @default.
- W2230481302 hasAuthorship W2230481302A5042806568 @default.
- W2230481302 hasAuthorship W2230481302A5048477205 @default.
- W2230481302 hasAuthorship W2230481302A5052280145 @default.
- W2230481302 hasAuthorship W2230481302A5077102924 @default.
- W2230481302 hasAuthorship W2230481302A5078273320 @default.
- W2230481302 hasAuthorship W2230481302A5078873882 @default.
- W2230481302 hasConcept C121608353 @default.
- W2230481302 hasConcept C126322002 @default.
- W2230481302 hasConcept C126894567 @default.
- W2230481302 hasConcept C143998085 @default.
- W2230481302 hasConcept C144301174 @default.
- W2230481302 hasConcept C146357865 @default.
- W2230481302 hasConcept C151730666 @default.
- W2230481302 hasConcept C2776235491 @default.
- W2230481302 hasConcept C2776694085 @default.
- W2230481302 hasConcept C2779466945 @default.
- W2230481302 hasConcept C2780192828 @default.
- W2230481302 hasConcept C2780923524 @default.
- W2230481302 hasConcept C2781190966 @default.
- W2230481302 hasConcept C38180746 @default.
- W2230481302 hasConcept C50382708 @default.
- W2230481302 hasConcept C71924100 @default.
- W2230481302 hasConcept C86803240 @default.
- W2230481302 hasConceptScore W2230481302C121608353 @default.
- W2230481302 hasConceptScore W2230481302C126322002 @default.
- W2230481302 hasConceptScore W2230481302C126894567 @default.
- W2230481302 hasConceptScore W2230481302C143998085 @default.
- W2230481302 hasConceptScore W2230481302C144301174 @default.
- W2230481302 hasConceptScore W2230481302C146357865 @default.
- W2230481302 hasConceptScore W2230481302C151730666 @default.
- W2230481302 hasConceptScore W2230481302C2776235491 @default.
- W2230481302 hasConceptScore W2230481302C2776694085 @default.
- W2230481302 hasConceptScore W2230481302C2779466945 @default.
- W2230481302 hasConceptScore W2230481302C2780192828 @default.
- W2230481302 hasConceptScore W2230481302C2780923524 @default.
- W2230481302 hasConceptScore W2230481302C2781190966 @default.
- W2230481302 hasConceptScore W2230481302C38180746 @default.
- W2230481302 hasConceptScore W2230481302C50382708 @default.
- W2230481302 hasConceptScore W2230481302C71924100 @default.
- W2230481302 hasConceptScore W2230481302C86803240 @default.
- W2230481302 hasIssue "16_suppl" @default.
- W2230481302 hasLocation W22304813021 @default.
- W2230481302 hasOpenAccess W2230481302 @default.
- W2230481302 hasPrimaryLocation W22304813021 @default.
- W2230481302 hasRelatedWork W179251896 @default.
- W2230481302 hasRelatedWork W2010765098 @default.
- W2230481302 hasRelatedWork W2051228185 @default.
- W2230481302 hasRelatedWork W2060708716 @default.
- W2230481302 hasRelatedWork W2154491681 @default.
- W2230481302 hasRelatedWork W2166976605 @default.
- W2230481302 hasRelatedWork W2299690226 @default.
- W2230481302 hasRelatedWork W2590008096 @default.
- W2230481302 hasRelatedWork W3081165226 @default.
- W2230481302 hasRelatedWork W93186087 @default.
- W2230481302 hasVolume "23" @default.
- W2230481302 isParatext "false" @default.
- W2230481302 isRetracted "false" @default.
- W2230481302 magId "2230481302" @default.
- W2230481302 workType "article" @default.